ArticleEuropean heart journal. Case reports2025
Thrombotic thrombocytopaenic purpura.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thrombotic thrombocytopaenic purpura (TTP) is a rare and potentially life-threatening form of thrombotic microangiopathy, characterized by thrombocytopaenia, haemolytic anaemia, neurological disturbances, and organ dysfunction. Clopidogrel is widely used in patients undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) due to its antiplatelet effects. However, the occurrence of TTP as an adverse effect of clopidogrel, though rare, requires greater awareness within the medical community. Case summary: We present a case of a female patient with symptoms of thrombocytopaenia, haemolytic anaemia, neurological disturbances, and renal impairment following clopidogrel administration after PCI for STEMI. The patient was diagnosed with TTP, which was confirmed by the resolving of the symptoms after the withdrawal of clopidogrel. Discussion: This case underscores the importance of awareness and prompt management of TTP as a serious adverse effect of clopidogrel. The main takeaway is the critical need for clinicians to recognize and address this rare complication to improve patient outcomes. Documenting such cases is essential to raise awareness among healthcare providers about this potentially life-threatening condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.